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Abstract 
Peripheral Arterial Disease (PAD) of lower limb with variable morbidity can be manifested as an 
asymptomatic, sever or life threatening disease. It is also a major cause of disability in many cases.  
The management of patients with PAD can be defined from a number of different treatment options in 
the terms of conservative-, interventional- and surgical therapies. 
Percutaneous Transluminal Angioplasty (PTA) using balloon catheter as a revascularization procedure 
has been used with acceptable outcomes. The method results are highlighted with comparable 
success—and patency rates, low complications, improving the quality of life and survival. We reviewed 
published studies and found that PTA is an appropriate alternative in the management of patient with 
Critical Limb Ischemia (CLI). Better outcomes have been achieved using Drug Coated Balloons (DCB) 
as well as Drug Eluting Stents (DES). Atherectomy remains with controversial results. Patient 
characteristics, the presence of associated risk factors, characteristics of lesions and accompanied 
cardiopulmonary disease may be the main challenges to use of these treatment options in the future. 
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1. Review Design 
This article was formulated with the aim of literature review on treated patient with CLI using PTA. 
Searches were conducted via the following databases, covering the period from their commencement to 
01/10/2018: Medline, Pre MEDLINE, EMBASE, Cochrane Library and other databases. In this review, 
are outlined the outcome of this technique and the authors’ views on the current status of treatments. 
 
2. Definition of Procedure  
Percutaneous Transluminal Angioplasty (PTA) of lower limb using balloon catheter has evolved since 
the 1960s (Becker & Dake, 2013). This procedure is a well-established treatment for Critical Limb 
Ischemia (CLI). It is indicated for documented stenosis > 50% of the vessel diameter, single stenosis 
and occlusions lesser than 10 cm in length, short consecutive multiple stenosis and also calcified 
occlusions (Pentecost et al., 1994; Athanasoulis, 1980). 
It should be not offered in active inflammation of a luminal stricture, sepsis, severe coagulopathy and 
recent surgical anastomotic stricture (Athanasoulis, 1980). 
Standard angiography and Magnetic Resonance Angiography (MRA) can provide a definition of 
occlusion anatomically and preoperative planning of revascularization but MRA could be considerable 
in patient with previously operation clips or endovascular stent and other MR imaging 
contraindications. Under local anesthesia and an antegrade puncture of the common femoral artery, a 
five or six French gauge sheath is positioned to perform a preliminary angiographic study using diluted 
(50%) non-ionic contrast medium (Gates et al., 2000). 
A guide wire and a French balloon catheter are used for the dilatation of 2-8 mm diameter arteries. Due 
to increase the risk of thrombosis especially in the infra popliteal arteries, stents are employed if 
dissection or suboptimal results occurred. During the procedure, 5000-7000 IU of sodium heparin is 
infused into the arterial lumen. If vessel spasm occurred, 0.1-0.2 mg of nitroglycerine is infused as an 
intra-arterial bolus. Intra-arterial thrombus is managed by catheter aspiration and/or urokinase and 
heparin infusion (Papavassiliou et al., 2003).  
A nephroprotection protocol is used in all non-dialyzed patients: 1500 ml salin is infused the day before 
and the day after the procedure. Creatinine value is determined the day before and after the PTA. In 
subjects with creatinine > 110 mg/dl, dopamine 2 mg/Kg/min is infused 24 h before and after the 
procedure. In patients with an ejection fraction < 40%, 20 mg of furosemide are injected intravenously 
at the beginning and the end of the daily hydration. Hospital stay can be 3 days. All the patients are 
prescribed either ticlopidine 500 mg/day or clopidogrel 75 mg/day for 30 days and subsequently acetyl 
salicylic acid 100 mg/day or ticlopidine 250 mg/day (Papavassiliou et al., 2003). 
This method offers faster recovery and requires shorter hospital stay. It requires no general anesthesia 
and maintains all option for extremity revascularization. PTA may be repeated if necessary and may be 
combined with surgery improving inflow or outflow of surgically placed graft. This method also may 
be considerable due to lower primary patency rate, multiple stenosis and may be limited due to 
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cost-benefit ration and necessary to reintervention (Mazari et al., 2012). 
 
3. Evaluation Parameters 
In the current review, success- and patency rates, complications, quality of life and survival rate were as 
the available evaluation parameters.  
Two forms of success rates include technical and clinical success. Technical success is defined as the 
substantial relief of stenosis or occlusion with residual narrowing of 20% or less, significant 
hemodynamic improvement, and no major morbidity (Society of Interventional Radiology Standards of 
Practice Committee, Guidelines for Percutaneous Transluminal Angioplasty, 2003). 
Clinical success in the femoropopliteal segment is defined as relief of or substantial improvement in 
symptoms, increase in the ankle-brachial index of at least 0.15 (Thom et al., 2011) and/or normalization 
of the popliteal pulse, thigh/calf pulse volume recording, or Doppler pressure (Society of Interventional 
Radiology Standards of Practice Committee, Guidelines for Percutaneous Transluminal Angioplasty, 
2003). The patency rate is the percentage of patients who have undergone an initially successful 
procedure for whom flow at the treatment site and symptomatic improvements are uninterrupted in any 
specified time period (Guidelines for Percutaneous Transluminal Angioplasty, 2003).  
Primary patency implies uninterrupted patency following the revascularization procedure being 
evaluated. Assisted primary patency expresses cases in which a revision of the revascularization 
method is applied to prevent impending occlusion or progression of stenosis. Secondary patency refers 
to patency of the initially treated vessel following a re-intervention to restore patency after occlusion 
(Dormandy et al., 2000). 
Complications parameters include; the amputation of treated limb with assessment of yearly evaluation 
of patient charts, surgical bypass of the trial leg, peri-procedural (within 30 days) complications, 
endovascular or surgical re-intervention of target lesion and death. Quality of life can be defined as an 
emotional well-being of satisfaction with a multidimensional construct comprising physical, 
psychological, social, and functional domains (Korolija et al., 2004). It can be measured by some 
methods such as McGill quality of life measurement questionnaire (McGill, 2004). 
Intermittent claudication is associated with a significant reduction in quality of life. Treatment of 
claudicants aims to reduce mortality from cardio-and cerebrovascular events and to improve quality of 
life. PTA is now widely used in the treatment of intermittent claudication (Cassar et al., 2003).  
To consider 1-, 2- and 3-years survival rates in patients with PAD using PTA versus stent or surgical 
treatment methods can clarify the role of PTA as an alternative therapy in the management of these 
patients.  
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4. Outcomes 
4.1 Technical Success Rate 
Table 1 illustrates the reported technical success rate of femoropopliteal PTA in patients with PAD. 
More than any other vascular segment, technical success and patency in the femoropopliteal artery 
depend on the characteristics of the lesion treated. Lesion classification has been defined by Society of 
Interventional Radiology Standards of Practice Committee according to the length, location of stenosis 
or occlusion and single or multiple lesions. The mean of technical success in reviewed studies was 
noted for 90.42% with sample Standard Deviation (SD) for 7.43% and Confidence Interval (CI) 
Approximations in level of 95% between 57.56% and 93.27% of patients with PAD (range 77-100%)  
 
Table 1. The Technical Success Rate of Femoropopliteal PTA in Patients with PAD 
Author Year No. of Patient PAT Limb Technical success rate 
Arfvidsson, B. et al  
Jørgensen, B. et al. 
Bakal, C. W. et al. 
London, N. J. et al.  
Söder, H. K. et al. 
Cejna, M. et al. 
Krankenberg, H. et al. 
Kudo, T. et al.  
Krankenberg, H. et al. 
Giles, K. A. et al. 
Romiti, M. et al.  
Airoldi, F. et al. 
Scatena, A. et al. 
Micari et al. 
Yang, et al. 
Joh, J. H. 
Thiny, P. O. 
Jang, S. J. 
Tnishibe, T. 
Ming, Z. 
Chang, Z. 
Korkmaz, K. 
Davis, T. 
Gray, W. A. 
1983  54  79.62 
1988  86  82 
1990 53 57  97 
1995   54 91 
2000 60  72 84 
2001 77   84 
2005 78 104  89.4 
2005 111   96.4 
2007 121   79 
2008 163  176 93 
2008    89 
2012 64 45  84 
2012 245 189  77 
2013 105   100 
2013 3789   92.29 
2014 76   90.5 
2015 53   96 
2015 87   100 
2016 65   94 
2016 183   80.4 
2016 147   93 
2017 755   84 
2017 123   100 
2017 241   98.3 
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Deloge, C.  
Brodmann, M. 
2018 53   100 
2018 35   97.1 
 
4.2 Clinical Success Rate 
Reviewed studies (Table 2) demonstrated the clinical success at 6 months of 73% and 92.7% of treated 
patients. The mean of clinical success was 68.1% with SD for 13.45% and CI- 95%; 60.14-76.05% of 
patients at 1- after PTA. This parameter was for at 2 years 77 and 65% of patients. 
Clock et al. in a study on 21 patients and 33 performed PTA reported clinical success at 3 years for 72% 
of patients after PTA. Loefberg et al. in 2011 performed 121 PTAs on 92 patients and reported 5 years 
clinical success of 27%. 
 
Table 2. The Clinical Success Rate after Femoropopliteal PTA in Patients with PAD 
Author year No. 
Patient 
PAT Limb Clininical 
Success 
(CS) at 6 
months 
CS 
at 1 
year
CS at 
2 
years 
CS at 
3 
years 
CS at 
5 
years
Arfvidsson, B. et al.  
Glock, et al. 
Fletcher, J. P. et al. 
London, N. J. et al.  
Söder, H. K. et al. 
Cejna, M. et al. 
Kudo, T. et al.  
Clock, et al. 
Loefberg, A. M. et al.  
Brodmann, M. et al. 
Scatena, A. et al. 
Sadaghianloo, N. et al. 
Jang, S. J. et al. 
Ming, Z. et al. 
Liu, X. et al. 
1983  54   77.4    
1984 21 33   72  92  
1986 63 91  73 58    
1995   54   77   
2000 60  72  63    
2001     72 65   
2005 111   92.7     
2007 21      72  
2011 92 121   40   27 
2011 33        
2012 245 189   60.4    
2013 34    65    
2015 87    77.5    
2016 183    92.8    
2018 100    71    
 
4.3 Patency Rates 
Table 3 shows the primary- and secondary patency rates and details using femoropopliteal PTA. Mean 
of reported primary patency rate at 1- and 2- years patient’s follow-up were 67.43 (SD, 19.7% and 
CI-95%, 60.00-74.87%) of treated. and 49 (SD for 5.29% and CI-95%; 43.01-54.98%) of patients 
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respectively.  
The mean of secondary patency rate at 1 year patient follow-up was achieved for 73.53 (SD; 18.42% 
and CI-95; 62.65-84.42%) of patients. 
Secondary patency rate at 1 year patient follow-up was achieved for 74 and 50.1% of patients. 
 
Table 3. The Primary and Secondary Patency Rate after Femoropopliteal PTA in Patients with 
PAD 
Author year No. Patient PAT Limb Primary 
patency 
rate (PPR) 
at 1 year 
PPR at 
2 years 
Secondary 
Patency (SPR) 
rate at 1 year 
SPR at 
2 years
 Engel, A. et al. 1982 192   83    
 Arfvidsson, B. et al.  1983  54  45    
 Gallino, A. et al.  1984 482 411  58    
 Jørgensen, B. et al. 1988  86  85    
 London, N. J. et al.  1995   54 78    
 Söder, H. K. et al. 2000 60  72 48  56  
 Cejna, M. et al. 2001    63 53 84 74 
 Jämsén, T. S. et al. 2002 178  218 46  63  
 Krankenberg, H. et al. 2005 78 104  81.9  91.5  
 Kudo, T. et al.  2005 111   31.4  79  
 DeRubertis, B. G. et al. 2007 184   54 43   
 Kristina, A. G. et al. 2008 163  176 53    
 Romiti, M. et al.  2008    77.4  83.3  
 Giles, K. A. et al. 2008 176   53 51   
 Casella, I. B. et al. 2010  48    63.7  
 Brodmann, M. et al. 2011 33   70.4  76.7  
 Micari, et al. 2013 105   72.4  84.7  
 Sadaghianloo, N. et al. 2013 34   13  32  
 Yang, et al. 2013 3789   57-65    
 Joh, J. H. et al. 2014 76   90.9    
 Laird, J. R. et al. 2015 331      50.1 
 Tnishibe, T. et al. 2016 65   81    
 De Athayde Soares, R. 2016 92   59.9    
 Chang, Z. et al. 2016 147   78  95  
 Deloge, C. et al. 2018 53   92    
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 Lucatelli, P. et al. 2018 31   88.9    
 Brodmann, M. et al. 2018 35   78.4    
 Kim, K. et al. 2018 244   67.5    
 Liu, X. et al. 2018 29   82.7    
 Lida, O. et al. 2018 100   89    
 
4.4 Complications 
Table 4 demonstrates the complication rate and details using femoropopliteal PTA. Reviewed studies 
showed the mean of complication rate of 8.38 (SD; 4.73% and CI-95%; 4.87-11.89%) of performed 
femoropopliteal PTA. The reported complications of the patients in whom PTA was attempted, included 
local hemorrhage, dissection, embolism, and spasm necessitating surgical intervention.  
The amputation of treated limb with assessment of yearly evaluation of patient charts was noted for 
5.68 (SD for 3.99% and CI-95%; 2.92-8.45% of cases. 
The mean of death which was a direct consequence of PTA reported for 3.88 (SD; 4.12% and CI-95%; 
0.58-7.18%) of treated patients. 
The mean of restenosis were reported for 35.8 with sample standard deviation for 26.73% and CI- 
Approximations in level of 95% between 21.67% and 50.01% of patients with PAD. 
Reintervention was performed for 34.81 (SD; 26.73% and CI-95%; 17.34-52.27%) of patients. 
The surgery at the time of angioplasty was reported in Glock’s study after 5.6% performed PTAs while 
in a study of Scatena A et al. in 2012, 1.5% patients needed to surgery. 
 
Table 4. The Complication Rate of Femoropopliteal PTA in Patients with PAD 
Author year No. 
Patient 
PAT Limb Amputation Death Re- 
stenoses 
Reintervention Complic
ation 
Engel A et al. 
Glock et al. 
Fletcher JP et al. 
Jørgensen B et al. 
Bakal CW et al. 
Hasson JE et al. 
Gapek P et al. 
H K Söder et al. 
Cejna M et al. 
Nasr M K et al. 
Jämsén TS et al. 
Becquemin JP et al. 
1982 192   9     
1984 21 33     49 7 
1986 63 91  9     
1988  86      10.9 
1990 53 57   1.8    
1990  202  10.9 5.9    
1991  217     32.7  
2000 60  72   32   
2001        5.2 
2002 526  608    87.5  
2002 178  218    32.6  
2003 115       3.3 
www.scholink.org/ojs/index.php/mshp                   Medical Science & Healthcare Practice                 Vol. 3, No. 1, 2019 
8 
Published by SCHOLINK INC. 
Krankenberg H et al. 
Schillinger M et al.  
Bai-xi Zhuang et al.  
Krankenberg H et al. 
DeRubertis BG et al. 
Kristina A Giles et al. 
Campbell W. B. et al. 
Faglia E et al. 
Brodmann M et al. 
Faglia E et al. 
Scatena A et al. 
Micari et al. 
Thiny PO 
Mostapha JA 
Lucatelli P 
Janco PJ et al. 
2005 78 104      5.8 
2006 104 53    43   
2007 150  176   13.7 7.2  
2007 121      18.3  
2007 184   1.9     
2008 163  176 3.4 5 63 61 9 
2009 33  37   21.2 15.2  
2009 554 420  8.2  22.4   
2011 33     39.4   
2012  308  2.6     
2012 245 189  0.5 10.6    
2013 105       17.5 
2015 53     75   
2016 407    0    
2018 31     12.9   
2018 69    0  9.8  
 
4.5 Quality of Life 
Keeling AN et al. in 2007 assessed the impact of 86 PTAs on Auality Of Life (QOL) in 72 patients with 
intermittent claudication or Critical Limb Ischemia (CLI).  
PTA results in improved QOL in patients with intermittent claudication and CLI as early as 1 month, 
which was shown to be maintained at 6 months in this small series.  
Cassar K et al. in 2003 examined the effect of PTA on Quality Of Life (QOL) in patients with intermittent 
claudication. The findings suggest that PTA may result in some improvement in QOL in these patients.  
Whyman MR et al. in a randomized controlled clinical trial determined in patients with mild and 
moderate intermittent claudication differences in outcome between PTA and conventional medical 
treatment after 2 years. They suggested that two years after PTA, patients had less extensive disease than 
medically treated patients, but this did not translate into a significant advantage in terms of improved 
walking or quality of life. There are important implications for patient management and future clinical 
research. 
4.6 Survival Rate  
The mean of survival rate at 1 year (Table 5) was calculated of 83.47 (SD; 12.78% and CI-95%; 
75.12%-91.82%) of patients. 
2- and 3-years survival rates were 71.66 with sample standard deviation for 15.14% and 
CI-Approximations (95%); 54.52%-88.8% of patients and 62.88 (SD for 12.25% and CI-95%; 
52.13%-73.62%) of patients with respectively (Table 5). 
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Table 5. Survival Rates in Patient with PAD Using PTA 
Author year No. 
Pat. 
PAT Limb Survival at 1 
year 
Survival at 2 
years 
Survival at 3 years 
Gapek, P. et al. 1991  217  81 61 56 
Becquemin, J. P. et al. 2003 115   92 89 82 
Laird, J. R. et al.  2006 155   82   
Kristina, A. G. et al. 2008 163  176 81 65 54 
Romiti, M. et al.  2008    98.3  68.4 
Bosiers, M. et al. 2008 51   79   
Giles, K. A. et al. 2008 176   81  54 
Arvela et al. 2011  274  57   
Lucatelli, P. et al. 2018 31   100   
 
5. Developed Endovascular Techniques  
In recently years many different endovascular techniques have been used for the management of 
peripheral artery diseases such as Drug-Coated Balloons (DCB), Bare Metal Stents (BMS) and 
Drug-Eluting Stents (DES) as well as numerous atherectomy devices.  
5.1 Drug Coated Balloon (DCB) 
The DCB delivers an anti-proliferative drug to the arterial wall during balloon angioplasty, 6-month 
primary patency of PTA in femoropopliteal disease with Drug-Coated (DCB) and Uncoated Balloons 
has been reviewed by Zhen Y et al. in 2018. They reported that DCB may improve early primary 
patency by inhibiting inflammation. A higher postoperative Neutrophil-Lymphocyte Ratio (NLR) was 
associated with early restenosis. Through a randomized trials in 2018 Chou HH et al. suggested that 
superior 2-year outcomes using DCB compared with uncoated balloon angioplasty and similar safety 
profiles in dialysis patients with femoropopliteal disease.  
5.2 Bare-Metal Stent (BMS) and Drug Eluting Stent (DES) 
Bare-metal stent is a stent with or without covering. Stent placement has been used with an acceptable 
success rate. Yang X et al. suggested that primary stent implantation had no advantage over balloon 
angioplasty in reducing restenosis or revascularization for infrapopliteal disease. Primary stent 
implantation seems to be a promising treatment for focal infrapopliteal lesions. Publication bias could 
not be ruled out, and the results should be treated with caution (Yang et al., 2014). 
Cejna M et al. reported that after stent placement, the primary success rate was significantly higher than 
after PTA. However, 1-year angiographic and clinical/hemodynamic success was not improved. 
An extensive review of the literature was carried out over the last 15 years by Caradu et al. (2016) on 
the use of BMSs in lower limb revascularization based on a PubMed (Medline). They reported that 
primary BMS implantation showed no advantage over PTA and as of today DES trials have not shown 
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enough clinical or economic benefit. Thus, BMSs are recommended over DESs, and only as a bailout 
strategy in case of flow limiting dissection or recoil. Quality trials assessing long-term clinically 
relevant outcomes, evolution in stents designs and vessel preparation could lead to a change in those 
recommendations. 
Liistro F et al. in 2009 reported that repeat balloon angioplasty for DES restenosis showed similar 
clinical outcome compared to re-DES (homo- or hetero-) implantation and could be considered as first 
treatment strategy in this setting. 
Torii S et al. in 2018 reported that in the treated arteries, irrespective of preceding DCB treatment or 
PTA, DES treatment showed maximum drug effects vs DCB alone or in combination with BMS 
placement, and there was no detrimental toxic effect in DCB-treated iliofemoral arteries before DES 
treatment compared with PTA before DES treatment. Downstream vascular changes were exclusively 
seen in groups treated with DCBs. 
5.3 Atherectomy 
Abdollah O et al. in 2018 reported that PTA alone and atherectomy-PTA was associated with similar 
outcomes in terms of vessel dissection and residual stenosis, mortality at 12months, and limb 
amputation at 1 or 12months. But Janas et al. in 2017 compared long-term outcomes after percutaneous 
PTA and atherectomy in patients requiring endovascular revascularization and showed that ahterectomy 
was associated with lower risk of Target Lesion Revascularization (TLR). 
Shammas et al. (2018) in a single center cohort of Jetstream Atherectomy (JA) followed 311 procedures 
and reported that JA with DCB had a superior TLR rate up to 16-month follow-up when compared to 
JA with PTA in treating all comers’ femoropopliteal artery disease. 
 
6. Discussion 
Percutaneous transluminal angioplasty using balloon catheter can be performed as the first choice in 
treatment of the CLI with high success- and patency rates, low complication rate, increase the quality 
of life and providing an acceptable survival.  
The outcomes of PTA have been evaluated comparatively with other treatment options. Romiti M et al. 
in a meta-analysis of 30 related studies presented that the technical success and subsequent durability 
of angioplasty are limited compared with bypass surgery, but the clinical benefit is acceptable because 
limb salvage rates are equivalent to bypass surgery. Limb salvage was noted for 95.4% patients at 1 
year and 82.4% at 3 years. 
Janczak, D. et al. in 2017 suggested that the endovascular method results in a similar re-operation rate 
and number of complications as open surgery.  
Reasons for unsuccessful PTA are mainly difficulties in passing the stenosis/occlusion with the guide 
wire or that dilation cannot be completed because of extensive calcification in the arterial wall.  
Many reports suggest that PTA is a satisfactory alternative to surgical treatment of occlusion of the 
infrapopliteal arteries. Nasr, M. K. et al. demonstrated that PTA is increasingly replacing bypass 
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surgery in the treatment of CLI, without compromising patient survival or limb salvage rates. They 
achieved the limb salvage in 89% patient at 1 year and 87% at 5 years. Giles KA et al. showed that the 
excellent limb salvage rates may be obtained with careful follow-up and reinterventions when 
necessary.  
Retrograde tibiopedal access and interventions have contributed to advance of endovascular techniques 
to treat Critical Limb Ischemia (CLI) patients. Mustapha JA in a review of infrapopliteal angioplasty in 
2017 showed that retrograde pedal access has emerged as an important tool to facilitate successfully 
percutaneous revascularization and limb salvage in patients with CLI. Retrograde tibial-pedal access 
has shown improvement in the rate of successful revascularizations (Mustapha et al., 2017). 
Subintimal recanalization is one of treatment options with this technique; a channel is deliberately 
created by dissecting the vessel wall in order to replace the native occluded lumen. This is opposed to 
intraluminal recanalization, where passage of an arterial obstructive lesion is performed by central 
luminal navigation. Bosiers et al. in 2012 presented that in lower extremity PTAs intraluminal is better 
than subintimal. 
Kim K et al. in 2018 suggested that in long femoropopliteal occlusions, the subintimal approach 
achieved a higher technical success rate and similar mid-term primary patency and TLR-free survival 
compared with intraluminal approach. 
Jaemsen TS et al. reported that although the long-term patency rates of femoropopliteal PTA in 
claudicant patients were poor, the acceptable number of reinterventions and the low frequency of 
development of CLI imply the long-term benefits achievable with this treatment. 
Hunink et al. evaluated the cost-effectiveness of PTA and bypass surgery in patient with stenotic or 
occlusive PAD and suggested that PTA is the preferred initial treatment in patients with disabling 
claudication and a femoropopliteal stenosis or occlusion and in those with chronic critical ischemia and 
a stenosis. Bypass surgery is the preferred initial treatment in patients with chronic critical ischemia 
and a femoropopliteal occlusion.  
Age may be as an important factor in the treatment of patients with PAD. Arvela et al. in 2011 reported 
that when feasible, a strategy of PTA first appears to achieve better results than infrainguinal bypass 
surgery in patients aged 80 years and older.  
Associated risk factors such as diabetes mellitus can change the outcome of treatment options. Fagila E 
et al. evaluated the long-term prognosis of Critical Limb Ischemia (CLI) in diabetic patients. They 
reported that diabetic patients with CLI have high risks of amputation and death. In a dedicated diabetic 
foot center, the major amputation, ulcer recurrence, and major contralateral limb amputation rates were 
low. Coronary Artery Disease (CAD) is the leading cause of death and in patients with CAD history the 
impaired ejection fraction is the major independent prognostic factor. 
Fagila et al. in 2009 also evaluated the feasibility of peripheral revascularization by PTA or By Pass 
Grafting (BPG) in diabetic patients with Critical Limb Ischemia (CLI). They presented that 
revascularization by PTA is highly feasible in diabetics with CLI. The feasibility of revascularization 
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by BPG is lower but nonetheless consistent. Darling et al. in 2018 reported that a bypass-first strategy 
is associated with similar 30-day outcomes and lower restenosis and reintervention rates. These data 
suggest that a bypass-first approach may best serve appropriately selected, anatomically suitable 
patients with diabetes mellitus and pedal ischemia that requires revascularization. 
In conclusion, PTA is an appropriate method with comparable outcomes in patients with critical limb 
ischemia. Better outcomes have been achieved using drug coated balloon as well as drug eluting stent. 
Atherectomy remains with controversial results. Patient characteristics such as gender, age and life 
style, characteristics of lesions, presence of associated risk factors and accompanied cardiopulmonary 
disease may be the major future challenges of treating PAD using PTA. 
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